Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma

Clinical Cancer Research

Volumn 6, Issue 12, 2000, Pages 4739-4744

  Marrogi, Aizen J ^a   Travis, William D ^b   Welsh, Judith A ^a   Khan, Mohammed A ^a   Rahim, Haress ^a   Tazelaar, Henry ^c   Pairolero, Peter ^c   Trastek, Victor ^c   Jett, James ^c   Caporaso, Neil E ^a   Liotta, Lance A ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; CYCLOOXYGENASE 2; NITRIC OXIDE SYNTHASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; ENZYME BLOOD LEVEL; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; CYTOPLASM; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOKINES; MALE; MEMBRANE PROTEINS; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SMOKING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034488632     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Tumoral vascularity as a prognostic factor in cancer
2. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression
3. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
4. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer
5. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer
6. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers
7. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
8. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53
9. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
10. Chemopreventive activity of Celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
11. Hypoxia and the regulation of gene expression
12. Upregulation of NOS2 expression in cancer-prone p53 knockout mice
13. Hypoxia induces cyclooxygenase-2 via the NF-κB p65 transcription factor in human vascular endothelial cells
14. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium
15. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
16. Thrombospondin-1 is a major activator of TGF-β1 in vivo
17. Inhibition of cyclooxygenase-2 gene expression by p53
18. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild-type p53
19. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer
20. Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer
21. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival
22. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis
23. Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma
24. Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer
25. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma
26. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis
27. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon
28. Gender comparisons in human lung cancer: Analysis of p53 mutations, anti-p53 serum antibodies and c-erbB-2 expression
29. Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma
30. Nitric oxide synthase activity in human lung cancer
31. Female lung cancer
32. Estrogen and progesterone receptors in bronchogenic carcinoma
33. A specific spectrum of p53 mutations in lung cancer from smokers: Review of mutations compiled in the IARC p53 database
34. p53 gene and K-ras mutations in lung cancers from ex-, passive or never smoking females in a population-based case-controlled study
35. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39: Correlation with p53 and angiogenic factor expression
36. Immunohistochemical study on tumor angiogenic factors in non-small cell lung cancer
37. Biological characterization of subgroups of squamous cell lung carcinomas
38. Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
39. Clinical potential of matrix metalloprotease inhibitors
40. Anticancer drug targets: Approaching angiogenesis
41. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
42. Clinical trials referral resource. Clinical trials using thalidomide